RNS23 Jun 2020 23:11
The lack of nous by financial commentators astounds me. Most of the RNS was irrelevant, FY 2019 now audited & confirmed as per drafts previously released. Q1 reaffirmed, the only significant factor arising was the massive uplift in Vametco valuation which finds itself in the P& L account, I presume as an extraordinary item. Nevertheless less very positive.
Fortune then has a podcast & tells us sales to China have trebled, how canny is that with V Sales nearly 25% higher than the ROW. We are also told that China’s needs are increasing. A perfect storm awaits.